Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 14/20 | 0.54 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3775310 | 0.89 | GRM4 (0.57) | GRM4LRRK2KDR | |
| SCHEMBL3775370 | 0.85 | LRRK2 (0.63) | GRM4LRRK2KDRMEN1KMT2A | |
| SCHEMBL13060922 | 0.84 | MAPT (0.45) | GRM4LRRK2NPSR1MEN1KMT2A | |
| SCHEMBL3771231 | 0.83 | GRM4 (0.56) | GRM4MEN1KMT2A | |
| SCHEMBL3775329 | 0.82 | LRRK2 (0.61) | GRM4LRRK2KDR | |
| SCHEMBL3775905 | 0.82 | LRRK2 (0.46) | GRM4LRRK2MEN1KMT2A | |
| SCHEMBL13060923 | 0.81 | LRRK2 (0.41) | GRM4LRRK2 | |
| SCHEMBL3764191 | 0.81 | LRRK2 (0.45) | GRM4LRRK2 | |
| SCHEMBL3768341 | 0.80 | GRM4 (0.59) | GRM4LRRK2NPSR1KMT2A | |
| SCHEMBL3763899 | 0.80 | GRM4 (0.51) | GRM4LRRK2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170320870-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2017-11-09 | — | — | US | disclosed |
| US-20170320870-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2017-11-09 | — | — | US | disclosed |
| US-20170320870-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2017-11-09 | — | — | US | disclosed |
| EP-2408772-B1 | COMPOUNDS | MEDICAL RES COUNCIL TECHNOLOGY (GB) | 2015-07-01 | — | — | EP | disclosed |
| US-20100317646-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-12-16 | — | — | US | disclosed |
| US-20100317646-A1 | COMPOUNDS | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2010-12-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170320870-A1 | COMPOUNDS | CBR3, CNR1, HCAR3 | GRM4 1109/4885LRRK2 2309/4885NPSR1 57/4885 |
| US-20100317646-A1 | COMPOUNDS | CBR3, CNR1, HCAR3 | GRM4 1107/4885LRRK2 2208/4885NPSR1 59/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.